Vibe Coding Moves Beyond the Proteomics Prototype
-
By
-
James Strachan
-
September 30, 2026
-
14 min
By
James Strachan
September 30, 2026
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
A dedicated syndicate is connecting academia, industry, and people with cystic fibrosis to advance diagnostic research
September 17, 2026